These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8169794)

  • 1. Antiplatelet activity of nipecotamides in experimental thrombosis in mice.
    Lawrence WH; Howell RD; Gollamudi R
    J Pharm Sci; 1994 Feb; 83(2):222-5. PubMed ID: 8169794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activities of the novel antiplatelet agent alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide.
    Lyman BA; Bond SE; Dillingham EO; Lawrence WH; Gollamudi R
    Res Commun Chem Pathol Pharmacol; 1992 Dec; 78(3):279-88. PubMed ID: 1475529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective antiplatelet actions of nipecotamides.
    Gollamudi R; Feng Z; Dillingham EO; Bond SE; Han G; Salgia S
    Thromb Res; 1993 Feb; 69(4):361-7. PubMed ID: 8470057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PAF-induced human platelet aggregation by antithrombotic nipecotomides.
    Herron D; Dillingham EO; Lyman BA; Zheng X; Bond SE; Salgia SR; Gollamudi R
    Prostaglandins Leukot Essent Fatty Acids; 1995 May; 52(5):309-18. PubMed ID: 7630919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of piperidine-3-carboxamides as human platelet aggregation inhibitors.
    Zheng X; Salgia SR; Thompson WB; Dillingham EO; Bond SE; Feng Z; Prasad KR; Gollamudi R
    J Med Chem; 1995 Jan; 38(1):180-8. PubMed ID: 7837229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet effects of R,S-(meso)-alpha, alpha'-bis[3-(N,N-diethylcarbamoyl) piperidino]-p-xylene ex vivo in the dog and in vivo in the mouse.
    Han G; Bannerman D; Handa RK; Dillingham EO; Lawrence WH; Gollamudi R
    Gen Pharmacol; 1997 Apr; 28(4):617-21. PubMed ID: 9147034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of platelet aggregation inhibitory activity by phenyl amides and esters of piperidinecarboxylic acids.
    de Candia M; Summo L; Carrieri A; Altomare C; Nardecchia A; Cellamare S; Carotti A
    Bioorg Med Chem; 2003 Apr; 11(7):1439-50. PubMed ID: 12628670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytosolic ionized calcium in human platelets: the influence of collagen and a novel antiplatelet agent.
    Gollamudi R; Dillingham EO; Bond SE; Lyman BA
    Biochem Biophys Res Commun; 1991 Jun; 177(2):888-93. PubMed ID: 2049109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of thrombus formation in vivo by novel antiplatelet agent.
    Marzec UM; Kelly AB; Hanson SR; Lasslo A; Harker LA
    Arteriosclerosis; 1990; 10(3):367-71. PubMed ID: 2140503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary in vivo studies on the platelet aggregation inhibitory activity of alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide in beagle dogs.
    Lawrence WH; Gollamudi R; Dillingham EO; Carter-Burks G; Tisdelle PA; Lasslo A
    J Pharm Sci; 1988 May; 77(5):464-5. PubMed ID: 3411473
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic antiplatelet effects of a nipecotamide A-1C and low dose aspirin.
    Han G; Bond SE; Lawrence WH; Dillingham EO; Zheng X; Gollamudi R
    Gen Pharmacol; 1994 Nov; 25(7):1373-9. PubMed ID: 7896048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vintoperol on platelet aggregation and experimental thrombosis.
    Csomor K; Kárpáti E
    Arzneimittelforschung; 1994 Jan; 44(1):36-40. PubMed ID: 8135876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis.
    Tognolini M; Ballabeni V; Bertoni S; Bruni R; Impicciatore M; Barocelli E
    Pharmacol Res; 2007 Sep; 56(3):254-60. PubMed ID: 17709257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipophilicity-related inhibition of blood platelet aggregation by nipecotic acid anilides.
    De Marco A; De Candia M; Carotti A; Cellamare S; De Candia E; Altomare C
    Eur J Pharm Sci; 2004 Jun; 22(2-3):153-64. PubMed ID: 15158900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet agents affecting the interaction of Tissue Factor-Factor VIIa complex with Factor X in a continuous-flow reactor.
    Gir S; Reavis R; Turitto VT; Gollamudi R
    Biotechnol Appl Biochem; 1996 Feb; 23(1):63-6. PubMed ID: 8867897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity.
    Han BH; Suh DY; Yang HO; Park YH; Kang YH; Kim YC
    Arzneimittelforschung; 1994 Oct; 44(10):1122-6. PubMed ID: 7818584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular determinants of the platelet aggregation inhibitory activity of carbamoylpiperidines.
    Feng Z; Gollamudi R; Dillingham EO; Bond SE; Lyman BA; Purcell WP; Hill RJ; Korfmacher WA
    J Med Chem; 1992 Aug; 35(16):2952-8. PubMed ID: 1501222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative.
    Jin YR; Hwang KA; Cho MR; Kim SY; Kim JH; Ryu CK; Son DJ; Park YH; Yun YP
    Vascul Pharmacol; 2004 Feb; 41(1):35-41. PubMed ID: 15135330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene on human blood platelet structural physiology.
    Lasslo A; White JG
    Biochim Biophys Acta; 1984 Oct; 777(1):37-40. PubMed ID: 6435673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of subacute treatment with benzopyranopyrimidines in hemostasis and experimental thrombosis in mice.
    Ballabeni V; Calcina F; Tognolini M; Bruno O; Manotti C; Barocelli E
    Life Sci; 2004 Feb; 74(15):1851-9. PubMed ID: 14761666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.